sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
Compared to placebo it reduces mean IOP at 12 months in all groups of participants in this review. | Compared to placebo it may reduce mean IOP at 12 months in all groups of participants in this review. | 1 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may not be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | -1 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be associated with AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | -1 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | There is no evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | 0 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | In conclusion, this meta-analysis provides evidence that high 25OHD concentrations is protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | 1 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are not associated with late AMD. | -1 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are protective against late AMD. | -1 |
In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L are associated with late AMD. | In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50nmol/L may be associated with late AMD. | 1 |
Significant evidence for a relationship between T280M and V249I variants in CX3CR1 in the homozygote state with increased susceptibility to AMD was reported. | Significant evidence for a relationship between T280M and V249I variants in CX3CR1 in the homozygote state with decreased susceptibility to AMD was reported. | -1 |
Significant evidence for a relationship between T280M and V249I variants in CX3CR1 in the homozygote state with increased susceptibility to AMD was reported. | Weak evidence for a relationship between T280M and V249I variants in CX3CR1 in the homozygote state with increased susceptibility to AMD was reported. | 1 |
Lutein and zeaxanthin supplementation is a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. | Lutein and zeaxanthin supplementation is not a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. | -1 |
Lutein and zeaxanthin supplementation is a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. | Lutein and zeaxanthin supplementation is an unsafe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. | -1 |
Lutein and zeaxanthin supplementation is a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. | Lutein and zeaxanthin supplementation may be a safe strategy for improving visual performance of AMD patients, which mainly showed in a dose-response relationship. | 1 |
Combination of intravitreal anti-VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low-certainty. | Combination of intravitreal anti-VEGF plus intravitreal steroids appears to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low-certainty. | -1 |
There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti-VEGF plus steroid versus anti-VEGF alone. | There was a decreased rate of cataract development and raised intraocular pressure in eyes treated with anti-VEGF plus steroid versus anti-VEGF alone. | -1 |
The analysis of pooled data showed that aqueous humor TGF-β2 levels are elevated in patients with OAG and POAG. | The analysis of pooled data showed that aqueous humor TGF-β2 levels are not elevated in patients with OAG and POAG. | -1 |
The analysis of pooled data showed that aqueous humor TGF-β2 levels are elevated in patients with OAG and POAG. | The analysis of pooled data showed that aqueous humor TGF-β2 levels are decreased in patients with OAG and POAG. | -1 |
The analysis of pooled data showed that aqueous humor TGF-β2 levels are elevated in patients with OAG and POAG. | There is no evidence that aqueous humor TGF-β2 levels are elevated in patients with OAG and POAG. | 0 |
The analysis of pooled data showed that aqueous humor TGF-β2 levels are elevated in patients with OAG and POAG. | The analysis of pooled data showed that aqueous humor TGF-β2 levels may be elevated in patients with OAG and POAG. | 1 |
Within 3 mo, IVTA is more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | Within 3 mo, IVTA is not more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | -1 |
Within 3 mo, IVTA is more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | Within 3 mo, IVTA is less effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | -1 |
Within 3 mo, IVTA is more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | There is no evidence that within 3 mo, IVTA is more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | 0 |
Within 3 mo, IVTA is more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | Within 3 mo, IVTA may be more effective than is STTA in improving VA and reducing CMT in patients with refractory DME. | 1 |
Both PP GDD and AC GDD procedures had similar efficacy of reduction in the IOP and number of medications. | Both PP GDD and AC GDD procedures had similar efficacy of increase in the IOP and number of medications. | -1 |
Both PP GDD and AC GDD procedures had similar efficacy of reduction in the IOP and number of medications. | There is no evidence that both PP GDD and AC GDD procedures had similar efficacy of reduction in the IOP and number of medications. | 0 |
Microperimetry-assessed retinal sensitivity measurement may be more sensitive in detecting progression than other functional measures in non-neovascular AMD. | Microperimetry-assessed retinal sensitivity measurement may not be more sensitive in detecting progression than other functional measures in non-neovascular AMD. | -1 |
Microperimetry-assessed retinal sensitivity measurement may be more sensitive in detecting progression than other functional measures in non-neovascular AMD. | Microperimetry-assessed retinal sensitivity measurement may be less sensitive in detecting progression than other functional measures in non-neovascular AMD. | -1 |
Microperimetry-assessed retinal sensitivity measurement may be more sensitive in detecting progression than other functional measures in non-neovascular AMD. | There is no evidence that microperimetry-assessed retinal sensitivity measurement is more sensitive in detecting progression than other functional measures in non-neovascular AMD. | 0 |
Microperimetry-assessed retinal sensitivity measurement may be more sensitive in detecting progression than other functional measures in non-neovascular AMD. | Microperimetry-assessed retinal sensitivity measurement is more sensitive in detecting progression than other functional measures in non-neovascular AMD. | 1 |
Results from small preliminary studies show promising test performance characteristics both for the Amsler grid and PHP to rule out wet AMD in the screening setting. | Results from small preliminary studies do not show promising test performance characteristics both for the Amsler grid and PHP to rule out wet AMD in the screening setting. | -1 |
Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | Our analysis suggests that TREX does not deliver visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | -1 |
Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | Our analysis suggests that TREX delivers visual outcomes inferior to PRN and approaches similar efficacy to monthly injections. | -1 |
Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | There is no evidence that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | 0 |
Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | Our analysis suggests that TREX may deliver visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | 1 |
Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | Our analysis suggests that TREX delivers visual outcomes superior to PRN and has inferior efficacy to monthly injections. | -1 |
Our analysis suggests that TREX delivers visual outcomes superior to PRN and approaches similar efficacy to monthly injections. | Our analysis suggests that TREX delivers visual outcomes superior to PRN and may approach similar efficacy to monthly injections. | 1 |
This meta-analysis suggested that Val62Ile polymorphism was associated with susceptibility to AMD. | This meta-analysis suggested that Val62Ile polymorphism was not associated with susceptibility to AMD. | -1 |
This meta-analysis suggested that Val62Ile polymorphism was associated with susceptibility to AMD. | There is no evidence that Val62Ile polymorphism was associated with susceptibility to AMD. | 0 |
This meta-analysis suggested that Val62Ile polymorphism was associated with susceptibility to AMD. | This meta-analysis suggested that Val62Ile polymorphism might be associated with susceptibility to AMD. | 1 |
One study, with a total of 41 eyes, reported a beneficial effect of pretreatment with steroids on VA of -0.21 ETDRS logMAR units. | One study, with a total of 41 eyes, reported a detrimental effect of pretreatment with steroids on VA of -0.21 ETDRS logMAR units. | -1 |
Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | Although there is a lesser reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | -1 |
Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | Although there may be a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | 1 |
Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | Although there is a greater reduction in CFT in eyes pretreated with steroids, this consistently results in higher VA. | -1 |
Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in lower VA. | -1 |
Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | Although there is a greater reduction in CFT in eyes pretreated with steroids, there is no evidence that this consistently results in higher VA. | 0 |
Although there is a greater reduction in CFT in eyes pretreated with steroids, this does not consistently result in higher VA. | Although there is a greater reduction in CFT in eyes pretreated with steroids, this may not consistently result in higher VA. | 1 |
There is a small but statistically significant association between Aspirin use and early ARMD, which may warrant further investigation. | There is no statistically significant association between Aspirin use and early ARMD, which may warrant further investigation. | -1 |
There is a small but statistically significant association between Aspirin use and early ARMD, which may warrant further investigation. | There is no evidence of statistically significant association between Aspirin use and early ARMD, which may warrant further investigation. | 0 |
There is a small but statistically significant association between Aspirin use and early ARMD, which may warrant further investigation. | There is a statistically significant association between Aspirin use and early ARMD, which may warrant further investigation. | 1 |
This meta-analysis has thus revealed suggestive evidence for TLR3 rs3775291 as an associated marker for AMD in Caucasians but not in Asians. | This meta-analysis has thus revealed strong evidence for TLR3 rs3775291 as an associated marker for AMD in Caucasians but not in Asians. | 1 |
The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. | The studies showed no statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. | -1 |
The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. | There is no evidence of statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. | 0 |
rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. | rs1061170 might not be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. | -1 |
rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. | There is no evidence that rs1061170 is associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. | 0 |
rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. | rs1061170 is associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. | 1 |
The present meta-analyses indicated that there were no significantly associations between VEGF polymorphisms (rs833061, rs1413711, rs2010963) and the risk of AMD, although the association was different for each polymorphism among different populations. | The present meta-analyses indicated that there were significant associations between VEGF polymorphisms (rs833061, rs1413711, rs2010963) and the risk of AMD, although the association was different for each polymorphism among different populations. | -1 |
The present meta-analyses indicated that there were no significantly associations between VEGF polymorphisms (rs833061, rs1413711, rs2010963) and the risk of AMD, although the association was different for each polymorphism among different populations. | The present meta-analyses indicated that there may be no significant associations between VEGF polymorphisms (rs833061, rs1413711, rs2010963) and the risk of AMD, although the association was different for each polymorphism among different populations. | 1 |
Evidence for an association between MYOC.mt1 and the risk of POAG is limited. These results suggest that MYOC.mt1 polymorphism does not have significant influence on the risk of POAG development or its severity. | Evidence for an association between MYOC.mt1 and the risk of POAG is limited. These results suggest that MYOC.mt1 polymorphism has significant influence on the risk of POAG development or its severity. | -1 |
However, antidepressant drug treatment may be associated with significantly lower IOP and higher pupillary diameter. | However, antidepressant drug treatment may not be associated with significantly lower IOP and higher pupillary diameter. | -1 |
However, antidepressant drug treatment may be associated with significantly lower IOP and higher pupillary diameter. | However, antidepressant drug treatment may be associated with significantly higher IOP and higher pupillary diameter. | -1 |
However, antidepressant drug treatment may be associated with significantly lower IOP and higher pupillary diameter. | However, antidepressant drug treatment is associated with significantly lower IOP and higher pupillary diameter. | 1 |
However, antidepressant drug treatment may be associated with significantly lower IOP and higher pupillary diameter. | However, antidepressant drug treatment may be associated with significantly lower IOP and lower pupillary diameter. | -1 |
The use of aspirin was not associated with the risk of AMD. | The use of aspirin was associated with the risk of AMD. | -1 |
The use of aspirin was not associated with the risk of AMD. | There is no evidence that the use of aspirin is associated with the risk of AMD. | 0 |
The use of aspirin was not associated with the risk of AMD. | The use of aspirin may not be associated with the risk of AMD. | 1 |
AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in patients with NVG. | AGV implantation with adjuvant bevacizumab was not more effective and did not have a higher success rate than surgery alone for lowering IOP in patients with NVG. | -1 |
AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in patients with NVG. | AGV implantation with adjuvant bevacizumab was less effective and had a lower success rate than surgery alone for lowering IOP in patients with NVG. | -1 |
AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in patients with NVG. | here is no evidence that AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in patients with NVG. | 0 |
The combined procedure tended to show a lower incidence of bleeding-associated complications, such as hyphema. | The combined procedure did not tend to show a lower incidence of bleeding-associated complications, such as hyphema. | -1 |
The combined procedure tended to show a lower incidence of bleeding-associated complications, such as hyphema. | The combined procedure tended to show a higher incidence of bleeding-associated complications, such as hyphema. | -1 |
The combined procedure tended to show a lower incidence of bleeding-associated complications, such as hyphema. | The combined procedure showed a lower incidence of bleeding-associated complications, such as hyphema. | 1 |
Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. | Overall, the evidence suggests that symptoms of depression are not more prevalent amongst AMD populations than anxiety symptoms. | -1 |
Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. | Overall, the evidence suggests that symptoms of depression are less prevalent amongst AMD populations than anxiety symptoms. | -1 |
Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. | Overall, there is no evidence that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. | 0 |
Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. | Overall, the evidence suggests that symptoms of depression may be more prevalent amongst AMD populations than anxiety symptoms. | 1 |
Individuals with myopia have an increased risk of developing open-angle glaucoma. | Individuals with myopia do not have an increased risk of developing open-angle glaucoma. | -1 |
Individuals with myopia have an increased risk of developing open-angle glaucoma. | Individuals with myopia have a decreased risk of developing open-angle glaucoma. | -1 |
Individuals with myopia have an increased risk of developing open-angle glaucoma. | There is no evidence that individuals with myopia have an increased risk of developing open-angle glaucoma. | 0 |
Individuals with myopia have an increased risk of developing open-angle glaucoma. | Individuals with myopia may have an increased risk of developing open-angle glaucoma. | 1 |
The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing PEXS/PEXG. | The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were not associated with a reduced risk of developing PEXS/PEXG. | -1 |
The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing PEXS/PEXG. | The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a increased risk of developing PEXS/PEXG. | -1 |
The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing PEXS/PEXG. | There is no evidence that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing PEXS/PEXG. | 0 |
The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing PEXS/PEXG. | The meta-analysis suggested that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC might be associated with a reduced risk of developing PEXS/PEXG. | 1 |
Both trabeculectomy and canaloplasty can significantly reduce the intraocular pressure in glaucoma patients at 12 months after operation, trabeculectomy leads a more marked IOP decrease than canaloplasty at the cost of a higher complication rate and more demanding for postoperative care. | Both trabeculectomy and canaloplasty can significantly reduce the intraocular pressure in glaucoma patients at 12 months after operation, trabeculectomy leads a more marked IOP increase than canaloplasty at the cost of a higher complication rate and more demanding for postoperative care. | -1 |
Both trabeculectomy and canaloplasty can significantly reduce the intraocular pressure in glaucoma patients at 12 months after operation, trabeculectomy leads a more marked IOP decrease than canaloplasty at the cost of a higher complication rate and more demanding for postoperative care. | Both trabeculectomy and canaloplasty can significantly reduce the intraocular pressure in glaucoma patients at 12 months after operation, trabeculectomy may lead a more marked IOP decrease than canaloplasty at the cost of a higher complication rate and more demanding for postoperative care. | 1 |
Self-management programs appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. | Self-management programs do not appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. | -1 |
Self-management programs appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. | Self-management programs appear ineffective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. | -1 |
Self-management programs appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. | There is no evidence that self-management programs appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. | 0 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost are not superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | -1 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost are inferior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | -1 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | There is no evidence that travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | 0 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost may be superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | 1 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost are superior in IOP control than latanoprost, and latanoprost is not better tolerated in patients with CACG. | -1 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost are superior in IOP control than latanoprost, and latanoprost is tolerated worse in patients with CACG. | -1 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost are superior in IOP control than latanoprost, but there is no evidence that latanoprost is better tolerated in patients with CACG. | 0 |
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG. | Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost may be better tolerated in patients with CACG. | 1 |
The epidemiological literature published to date indicates that individuals with more sunlight exposure are at a significantly increased risk of AMD. | The epidemiological literature published to date indicates that individuals with more sunlight exposure are not at a significantly increased risk of AMD. | -1 |
The epidemiological literature published to date indicates that individuals with more sunlight exposure are at a significantly increased risk of AMD. | The epidemiological literature published to date indicates that individuals with more sunlight exposure are at a significantly decreased risk of AMD. | -1 |
The epidemiological literature published to date indicates that individuals with more sunlight exposure are at a significantly increased risk of AMD. | The epidemiological literature published to date indicates that individuals with more sunlight exposure may be at a significantly increased risk of AMD. | 1 |
There is very low-quality evidence that treatment with iStent may result in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | There is very low-quality evidence that treatment with iStent may not result in higher proportions of participants who are drop-free or achieving better IOP control, in the short, medium, or long-term. | -1 |